Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification. READ ARTICLE

Current Oncology DOI:10.3390/curroncol29010016

Authors: Walid Shalata, Alexander Yakobson, Rachel Steckbeck, Ashraf Abu Jama, Omar Abu Saleh and Abed Agbarya

Case Study, group1Kirk SmithDecember 31, 2021lung adenocarcinoma, ALK mutation, Alectinib, alkaline phosphatase, toxicity

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination.

Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2021.04.008

Authors: Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess

EP116-28 ALK Translocated Patients: Survival in an Unselected Population

A cohort of 34 patients diagnosed of non-small cell lung cancer with ALK translocation were retrospectively analyzed in our center between 2008-2018. Baseline demographics characteristics were described. OS was calculated as the main objective.Patients were followed a median of 47 months (IQR 30-203). Median age was 59 years (IQR 36-83), being 47% male and 53% female. 44% were never smokers and 58% had any comorbidities. At diagnosis, 83% were symptomatic and the most frequent metastases were bone ones (32%). Complete baseline characteristics are shown in Table 1. Median OS was 32 months (IQR 15-78). 1-year, 2-year and 3- year survival was 75%, 69% 49.9% respectively. The ALK translocation and targeted treatments have led to a dramatic improvement in overall survival in clinical trials confirmed in our series. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.2393

Authors: B. Núñez-García, R. Gómez-Bravo, J.C. Sánchez, B. Cantos, M. Méndez, A.M. Morito, M. Blanco, V. Calvo, M. Provencio